Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 2 of 45 for:    Open Studies | "Mucopolysaccharidoses"

Natural History Studies of Mucopolysaccharidosis III

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Nationwide Children's Hospital
Sanfilippo Children's Research Foundation
The Sanfilippo Research Foundation
The Children's Medical Research Foundation
Information provided by (Responsible Party):
Kevin Flanigan, Nationwide Children's Hospital Identifier:
First received: November 26, 2013
Last updated: January 15, 2014
Last verified: January 2014

The purpose of this study is to assess rates of decline in motor and cognitive functional measures, and to assess potential biomarkers, in order to identify potential outcome measure appropriate for use in therapeutic clinical trials.

Condition Intervention
Mucopolysaccharidosis Type IIIA
Mucopolysaccharidosis Type IIIB
Procedure: Lumbar puncture
Device: Magnetic Resonance Imaging (MRI) of the brain

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Natural History Studies of Mucopolysaccharidosis III

Resource links provided by NLM:

Further study details as provided by Nationwide Children's Hospital:

Primary Outcome Measures:
  • Cognitive function [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
    Assessed using the Leiter International Performance assessment, a non-verbal assessment of cognitive function.

Secondary Outcome Measures:
  • Adaptive functioning [ Time Frame: Months 0, 6, and 12 ] [ Designated as safety issue: No ]
    Parental assessment of adaptive functioning using the Adaptive Behavioral Assessment System

  • Emotional/behavioral function [ Time Frame: Months 0, 6, and 12 ] [ Designated as safety issue: No ]
    Assessment of emotional/behavioral problems using the Child Behavioral Checklist

  • White and grey matter brain volumes [ Time Frame: Months 0 and 12 ] [ Designated as safety issue: No ]
    Assessment of brain volumes by MRI. MRI will be performed under sedation.

Other Outcome Measures:
  • Serum and cerebrospinal fluid NAGLU (MPSIIIB subjects) or SGSH (MPSIIIA subjects) levels [ Time Frame: Months 0 and 12 ] [ Designated as safety issue: No ]
    Measurement of NAGLU or SGSH activity in serum (by venipuncture) and CSF (by lumbar puncture). Lumbar puncture will be performed under sedation.

  • Liver size [ Time Frame: Months 0 and 12 ] [ Designated as safety issue: No ]
    Liver volume will be assessed by abdominal MRI obtained under the same sedation event as brain MRI and lumbar puncure.

Biospecimen Retention:   Samples With DNA

Biobanking will include:

  1. Serum/Plasma
  2. Cerebrospinal fluid

Estimated Enrollment: 30
Study Start Date: August 2013
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
MPS IIIA/B Subjects
Cohort will be followed for one year to assess natural history of the disease.
Procedure: Lumbar puncture Device: Magnetic Resonance Imaging (MRI) of the brain

Detailed Description:

Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) is a group of four devastating genetic diseases that result in the abnormal accumulation of glycosaminoglycans in body tissues. In MPSIII the predominant symptoms occur due to accumulation within the central nervous system (CNS), including the brain and spinal cord, resulting in cognitive decline, motor dysfunction, and eventual death.

In anticipation for future therapeutic studies for MPSIIIA and MPSIIIB, we are performing a natural history study with the following goals:

  1. To identify individual rates of decline in motor and cognitive function in a cohort of potential clinical trial patients.
  2. To study the natural history of outcome measures in order to assess their appropriateness as outcomes in an eventual trial.
  3. To establish baseline functional data in patients who will be potential candidates for an eventual trial.
  4. To identify biomarkers of disease progression over a 12-month interval, including changes in brain MRI and in cerebrospinal fluid.

This study will last a year. Patients in this study will need to come to Nationwide Children's Hospital in Columbus, Ohio three times: at enrollment (visit 1), at 6 months (visit 2), and at 12 months (visit 3). During visits 1 and 3, an MRI and a lumbar puncture will be performed.


Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Individuals affected by MPS IIIA or MPS IIIB will be considered for this study.


Inclusion Criteria:

  1. Age 2 years old or greater
  2. Confirmed diagnosis of MPSIIIA or MPSIIIB by either of two methods:

    1. No detectable or significantly reduced NAGLU (MPSIIIB) or SGSH (MPSIIIA) activity in serum or leukocyte assay
    2. Genomic DNA mutation analysis demonstrating a homozygous or compound heterozygous mutations in the NAGLU (MPSIIIB) or SGSH (MPSIIIA) genes
  3. Clinical history of or examination features of neurologic dysfunction.

Exclusion Criteria:

  1. Inability to participate in the clinical evaluations
  2. Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics
  3. Inability to be safely sedated in the opinion of the clinical anesthesiologist
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02037880

Contact: Krista Kunkler 614.722.2238

United States, Ohio
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
Contact: Krista Kunkler    614-722-2238   
Principal Investigator: Kevin Flanigan         
Sponsors and Collaborators
Nationwide Children's Hospital
Sanfilippo Children's Research Foundation
The Sanfilippo Research Foundation
The Children's Medical Research Foundation
Principal Investigator: Kevin M Flanigan, MD Nationwide Children's Hospital, Columbus, Ohio
  More Information

No publications provided

Responsible Party: Kevin Flanigan, MD, Nationwide Children's Hospital Identifier: NCT02037880     History of Changes
Other Study ID Numbers: MPSIII-1
Study First Received: November 26, 2013
Last Updated: January 15, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Nationwide Children's Hospital:

Additional relevant MeSH terms:
Mucopolysaccharidosis III
Carbohydrate Metabolism, Inborn Errors
Connective Tissue Diseases
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Mucinoses processed this record on November 25, 2014